Gut-Brain Axis Support.

This strain is one half of the long-standing R0052 plus R0175 combination used to study microbial signalling to the brain through vagal and metabolite routes. The two strains are typically formulated together.

R0175 is the bifidobacterial half of the same paired formulation, contributing a different fermentation profile and mucosal niche. Strain identity matters here because the signalling is not a genus-level property.

1714 is a characterised strain selected for effects on stress-axis and brain activity readouts rather than for digestive endpoints. It shows that the axis responds to specific strains, not to probiotics in general.

299v adheres to intestinal mucosa and ferments to lactate, changing the local environment where enteric nerve endings sit. It is one of the better characterised strains for gut comfort alongside mood readouts.

LGG supports tight junction protein expression and is the strain in which vagus-dependent central signalling was first mapped in animal work. Barrier integrity is the upstream condition for most axis effects.

This strain alters how tryptophan is partitioned between the serotonin route and the kynurenine route, which is one of the concrete biochemical bridges between gut microbes and brain chemistry.

GOS passes undigested to the colon where bifidobacteria ferment it to short-chain fatty acids, so it raises the population that the axis work depends on. Pairing a prebiotic with a strain is the definition of a synbiotic.

FOS resists upper gut digestion and is fermented in the proximal colon to acetate, propionate and butyrate, the metabolites that signal to enteric nerves and to the liver. It is a common prebiotic partner to a live strain.

Inulin is a longer fructan than FOS and ferments further along the colon, spreading short-chain fatty acid production over more of the bowel. Formulas often use both chain lengths together.

Partially hydrolysed guar ferments slowly and produces butyrate with little gas, which makes it the usual fibre choice when a sensitive gut cannot tolerate inulin. Same metabolite endpoint, different fermentation rate.

Resistant starch is fermented preferentially to butyrate, the short-chain fatty acid that colonocytes burn as fuel and that acts on enteric signalling. It shifts the metabolite mix rather than simply adding bulk.

Butyrate is the short-chain fatty acid that fibre fermentation is aimed at producing, so supplying it directly bypasses the need for a cooperative microbiome. It fuels colonocytes and acts on receptors on enteric nerve endings.

Tributyrin is a triglyceride of butyric acid that survives the stomach and releases butyrate on lipase cleavage further down. It solves the odour and early-absorption problem of butyrate salts.

Glutamine is the preferred fuel of the small intestinal lining and supports the tight junction proteins that keep the barrier selective. Barrier integrity sits upstream of most microbe-to-brain signalling.

Most of the body's serotonin is made in gut enterochromaffin cells from tryptophan, and gut microbes compete for that same amino acid. Supplying tryptophan feeds the substrate side of the axis directly.

5-HTP sits past tryptophan hydroxylase, the slow regulated step, so it converts to serotonin without competing at the amino acid transporter. It is the shorter route to the same molecule.

Aromatic amino acid decarboxylase needs pyridoxal-5-phosphate to convert 5-HTP into serotonin, so B6 status gates the last step. Without it, added precursor sits unconverted.

DHA is a structural lipid of the enteric and central nervous systems and also shifts the composition of the gut community when taken regularly. It works on both ends of the axis rather than one.

This yeast is not affected by antibacterial pressure and binds luminal toxins while supporting the mucosal layer. It is the usual companion when a formula must hold up under conditions that suppress bacterial strains.

Colostrum supplies immunoglobulins and growth factors that bind luminal antigens and support epithelial renewal. It is a barrier-side partner that works by a different route from fibre fermentation.

Theanine is structurally close to glutamate and modulates glutamatergic and GABAergic tone, which is the receptor end of the signalling that gut metabolites influence.

Magnesium blocks the NMDA receptor channel at rest and the glycine carrier is itself an inhibitory neurotransmitter, so the chelate contributes on both counts.

Berberine has wide antibacterial activity in the lumen and lowers the load of the same commensal populations a live strain is meant to build. Formulators separate the two doses in time rather than combining them in one capsule.

Charcoal adsorbs organic molecules indiscriminately in the gut lumen, including the amino acid precursors and botanical actives dosed alongside it. Anything taken with it is bound before it can be absorbed.

Lactobacillus plantarum species-level preparations feature widely in microbiota and mood research, and specific strains within it carry their own human data. Effects in this field are strain-specific, so a species name on a label is less informative than a strain designation. What most trials measure is a subjective questionnaire score or a faecal marker. Read species-level rows as category support rather than as evidence for a particular product.

Lactobacillus acidophilus appears across multi-strain formulas tested in this space, usually alongside bifidobacteria rather than alone. Its inclusion is formulation convention as much as a specific mechanistic claim. Where a blend shows an effect, the contribution of any one strain cannot be separated out. That limitation applies to every multi-strain trial in this literature.

Bifidobacterium lactis is among the more widely used and better-surviving commercial bifidobacteria and appears in blends across this category. Its documented endpoints sit mainly in gastrointestinal comfort and stool measures rather than central ones. The gut-to-brain part of the story is extrapolated from mechanism rather than measured for this species. Label it accordingly.

Psyllium is only partly fermented, so it works mostly through viscosity and stool form, with a smaller substrate contribution than the highly fermentable prebiotics. In this context it broadens the fibre mix rather than driving fermentation. It is also the gentler option for people who react badly to rapidly fermented prebiotics. The short-chain fatty acid pathway is where the mechanistic link to central signalling sits.

Pectin ferments readily and shifts short-chain fatty acid production, principally acetate and propionate. Those metabolites are the main proposed messengers in gut-to-brain signalling and are the endpoint most animal work in this field measures. A metabolite concentration is a marker, not a behavioural outcome. Gas is the practical dose-limiting factor.

Oat beta-glucan is fermented by colonic bacteria and adds to the substrate pool alongside the inulin and galactooligosaccharide entries already stored. Mixing substrate types feeds a wider range of organisms than any single prebiotic does. The mechanistic link to central signalling runs through short-chain fatty acids and vagal afferents. No trial has tested this fibre for a central endpoint.

An animal study reported that inulin acted on prefrontal GABAergic signalling through a microbiota to short-chain fatty acid to receptor pathway, which is one of the cleaner mechanistic demonstrations of the whole gut-to-brain proposition. It was measured in rodents, not people. The stored entry for this slug is inulin-chicory specifically; this row concerns inulin as the fibre. Read it as mechanism, not as a human outcome.

Methionine synthase needs cobalamin to remethylate homocysteine and regenerate S-adenosylmethionine, the universal methyl donor. Monoamine synthesis and inactivation both draw on that pool. Gut bacteria also both produce and consume B12, which is why the microbiome literature keeps returning to it. Established biochemistry rather than a tested combination.

5-methyltetrahydrofolate donates the methyl group that regenerates methionine and, from there, S-adenosylmethionine. A systematic review specifically examines folate and the human enteric microbiome, noting bacterial folate synthesis and consumption as a two-way relationship. That review names biological mechanisms rather than establishing an outcome. The cofactor relationship itself needs no citation.

Riboflavin becomes FAD, the cofactor MTHFR needs to produce methyl folate. Separately, riboflavin influences the redox environment in the colon in a way that favours certain anaerobic organisms. Both routes connect it to this area. The first is settled biochemistry; the second is a mechanistic observation.

Zinc contributes to tight junction integrity in the intestinal epithelium and is a cofactor across hundreds of enzymes. Barrier function is the first step in every mechanistic account of gut-to-brain signalling, since it governs what crosses. Zinc status also affects taste and appetite through unrelated routes. The barrier role is well characterised; the downstream central claim is inference.

Vitamin D receptor signalling in the gut epithelium affects tight junction protein expression and local immune tone, which is the barrier side of this system. Observational work links vitamin D status to microbiota composition, and an association is not a cause. The mechanistic receptor biology is solid; the microbiota link is correlational. Both should be labelled as such wherever they are shown.

EPA is the precursor for the E-series resolvins that participate in resolving inflammatory signalling, a distinct role from DHA's structural place in neuronal membranes. Most human trials in this space use a mixed EPA and DHA oil, so separating their contributions is rarely possible. Dietary omega-3 intake also shifts microbiota composition in some reports. That composition finding is a marker.

Glycine acts directly at its own inhibitory receptors and is one of the three amino acids making up glutathione. Both roles are relevant to a system framed around calm signalling and intestinal redox. It is also a common carrier amino acid in chelated mineral forms. The pairing logic is mechanistic; no combination trial exists.

Apigenin binds benzodiazepine sites in laboratory preparations, which is the usual explanation for chamomile's traditional calming use. Its poor absorption means a large share reaches the colon, where bacteria transform it into metabolites that may be the active species. That is the same two-way relationship seen across dietary polyphenols. Both halves are laboratory-level findings.

An animal study combined probiotics with dietary phenolics and reported enhanced parasympathetic tone through a gut-to-brain route, which is a direct test of the polyphenol-plus-probiotic pairing rather than an inference. Grape seed proanthocyanidins are poorly absorbed intact and are extensively metabolised by colonic bacteria into smaller phenolic acids. The measurement was in rats. Autonomic tone is a physiological marker, not a behavioural outcome.

Most ingested EGCG is not absorbed in the small intestine and reaches the colon, where bacteria cleave it into smaller phenolic metabolites that do enter circulation. The microbiome therefore determines what a person actually gets from a catechin dose, and it varies between people. That two-way relationship is the general polyphenol story. Caffeine content is a separate consideration if the extract is not decaffeinated.

A 2026 review examines selenium's role in intestinal and extra-intestinal health via microbiota regulation, and selenoproteins including the glutathione peroxidases govern redox conditions in the gut lining. Selenium has a narrow window between adequate and excessive intake, so stacking it across several products is the practical risk. The review is a secondary source summarising mechanism. No human outcome follows from it.

Lion's mane fruiting body is largely beta-glucan and chitin, which pass to the colon and are fermented, so it contributes substrate as well as its hericenone and erinacine fractions. Its own human data on cognitive measures is small and preliminary. The two roles are usually conflated on labels. Separating them is the honest reading.

Bacopa has a body of human trials on memory measures, taken over weeks rather than acutely. Its bacosides are poorly absorbed and subject to gut metabolism, which is where the connection to this area sits. It is a formulation companion rather than a mechanistic partner. Gastrointestinal upset is its most common reported complaint, which is worth noting when stacking it with fermentable fibres.

Chamomile's apigenin glycosides are cleaved by bacterial enzymes before absorption, making the microbiome part of the delivery chain rather than a separate target. It is also a long-standing digestive and calming infusion. The pairing is traditional with a mechanistic overlay. No combination trial exists.

Enterochromaffin cells in the gut synthesise melatonin from serotonin, and the total gastrointestinal content exceeds what the pineal gland produces. It acts locally on motility and on epithelial cells, separate from its circadian role. That makes it one of the clearer molecular bridges between the two systems. Supplemental melatonin's central sleep effect is a distinct question from its enteric one.